COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT

被引：0
|
作者：
Tan, E. C. H. [1 ]
Yang, M. C. [2 ]
机构：
[1] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan
[2] Natl Taiwan Univ, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE15
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
  • [32] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN
    Peral, C.
    Cordido, F.
    Gimeno, V
    Sanchez-Cenizo, L.
    Mir, N.
    Parrondo, J.
    VALUE IN HEALTH, 2017, 20 (09) : A557 - A558
  • [33] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [34] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [35] After standard treatment, do the second-line and third-line treatments make sense?
    Sabbatini, R
    Maur, M
    Mucciarini, C
    Conte, PF
    TUMORI, 2003, : S33 - S34
  • [36] A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES"
    Kohli-Lynch, Ciaran N.
    Ruiz-Negron, Natalia
    Beal, Amy
    Bellows, Brandon K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (08): : 1140 - 1141
  • [37] Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
    Smare, Caitlin
    Dave, Kiran
    Juarez-Garcia, Ariadna
    Abraham, Pranav
    Penrod, John R.
    Camidge, D. Ross
    Yuan, Yong
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1124 - 1133
  • [38] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [39] The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
    Ehlers, Lars H.
    Lamotte, Mark
    Ramos, Mafalda C.
    Sandgaard, Susanne
    Holmgaard, Pia
    Frary, Evan C.
    Ejskjaer, Niels
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (01) : 29 - 37
  • [40] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
12345